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GOING MULTIVARIATE IN CLINICAL
TRIAL STUDIES
A Bayesian framework for multiple binary
outcomes
Xynthia Kavelaars
DEPARTMENT OF METHODOLOGY AND STATISTICS, TILBURG UNIVERSITY, TILBURG, THE NETHERLANDS
Introduction
Clinical trials often compare a new treatment to standard care or a placebo. If
the collected data provide sufficient evidence that the new treatment is better
than the control treatment, the new treatment is declared superior. Since these
superiority decisions ultimately contribute to a decision about treatment adop-
tion, proper error control is crucial to ensure that better treatments are indeed
selected. Key to regulating decision errors is collecting sufficient information:
A quantity that is often expressed in terms of a minimum number of partici-
pants, or required sample size.
Recruiting sufficiently large samples can be challenging, however. This is espe-
cially true in an era in which medicine is increasingly personalized (Hamburg &
Collins, 2010; Ng, Murray, Levy, & Venter, 2009). Personalization of medicine refers
to the targeting of treatments at specific patient and/or disease characteristics under
the assumption that patients with different (disease) characteristics respond differ-
ently to treatments (Goldberger & Buxton, 2013). Since personalization limits the
target population of the treatment, inclusion and exclusion criteria for trials
become more stringent and the eligible number of participants decreases. This
inherently decreases the sample size of studies conducted with the same resources.
Consequences of small samples may be substantial: Trials may be left underpow-
ered and decisions about superiority might remain inconclusive.
The problem associated with small sample sizes due to stringent inclusion criteria is
illustrated by the CAR-B study (Schimmel, Verhaak, Hanssens, Gehring, & Sits-
koorn, 2018). CAR-B aims to improve treatment for cancer patients with 11–20
metastatic brain tumors (i.e. tumors that originate from another site in the body and
have spread to the brain). These patients have a life expectancy of one or two months
and are currently treated with whole-brain radiation therapy. However, whole-brain
radiation has adverse side effects: The treatment damages brain tissue and results in
severe cognitive impairment. Local radiation of the individual tumors (stereotactic
surgery) is a promising alternative that spares healthy tissue and prevents cognitive
decline without increasing mortality. The protective effect on cognition has been
demonstrated in a related population of patients with fewer brain tumors (Chang
et al., 2009; Yamamoto et al., 2014). However, investigating whether local radiation
reduces side effects in the current target population is difficult: Clinicians are reluctant
to prescribe the alternative treatment and not all referred patients are eligible for par-
ticipation, leaving the researchers unable to recruit the required sample.
To improve decision-making with limited samples, studies such as CAR-B
might combine information from multiple outcomes. The current chapter intro-
duces a Bayesian decision-making framework to combine two binary outcomes.
Since superiority with two outcomes can be defined in multiple ways, several cri-
teria to evaluate treatments are discussed in the “Decision rules” section. Evaluation
of these decision rules requires a statistical analysis procedure that combines the out-
comes. The “Data analysis” section outlines such a multivariate approach for Bayes-
ian analysis of binary outcomes. The proposed decision-making strategy is illustrated
in the “Computation in practice” section, which introduces an online app to ana-
lyze real data (for an online version go to https://utrecht-university.shinyapps.io/
multiple_binary_outcomes/ – for the annotated R code go to https://osf.io/
am7pr/ – and for potential newer versions go to https://github.com/XynthiaKave
laars). Since trials with limited access to participants aim for the smallest sample pos-
sible, the chapter continues with “Sample size considerations” to explain how
interim analyses during the trial may improve efficiency compared to traditional
sample size estimation before running the trial. The “Concluding remarks” section
highlights some extensions of the framework. Throughout the chapter, the com-
parison of local and whole-brain radiation in the CAR-B study serves as an example
with cognitive functioning and quality of life as the outcomes under consideration.
Decision rules
A key element of decision-making is the decision rule: A procedure to decide
whether a treatment is considered superior. When dealing with two outcomes,
superiority can be defined in several ways (Food and Drug Administration,
2017), such as a favorable effect on:
1. The most important outcome (“Single-outcome rule”)
2. Both outcomes (“All rule”)
3. Any of the outcomes (“Any rule”)
4. The sum of outcomes (“Compensatory rule”)
Each of these decision rules weighs the effects of the two outcomes differently.
The Single-outcome rule evaluates the data from one outcome and ignores the
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other outcome in the decision procedure. In the CAR-B study, local radiation
would be the treatment of preference if it impairs cognitive functioning less
than whole-brain radiation, irrespective of the effects on quality of life. The All
rule evaluates both outcomes, and requires favorable effects on each of them.
Compared to whole-brain radiation, more patients should maintain both cogni-
tive functioning and quality of life after local radiation. The Any rule requires
a beneficial effect on at least one outcome and ignores any result on the other
outcome. Local radiation would be considered superior if fewer patients experi-
ence cognitive side effects, a lower quality of life, or both. The Compensatory
rule also requires at least one favorable treatment effect, but the compensatory
mechanism poses a restriction on the second outcome. The new treatment may
perform better, similarly, or even worse than the control treatment on this out-
come, but the rule takes the size of the treatment differences into account to
weigh beneficial and adverse effects. A net advantage on the sum of outcomes is
required, such that several outcome combinations would result in a preference
for local radiation. Superiority is concluded as long as favorable effects on cogni-
tive functioning outweigh unfavorable effects on quality of life or vice versa.
The aforementioned decision rules ultimately lead to a conclusion about the
treatment difference: The new treatment is considered superior if the difference
between the new and the control treatment is larger than zero according to the
decision rule of interest. For each of the decision rules, the corresponding superior-
ity region is plotted in Figure 10.1. These superiority regions graphically represent
how the treatment differences on both individual outcomes should be related to
result in superiority: If the probability that the treatment difference falls in the
marked area is sufficiently large, the treatment would be declared superior.
Selecting a decision rule
The choice for a decision rule should be guided by the researcher’s standard for
superiority. To illustrate this, consider the following situations (see Figure 10.2
for a graphical representation):
1. Local radiation performs better on cognitive functioning as well as quality of life
2. Local radiation performs better on cognitive functioning and similarly on
quality of life
3. Local radiation performs much better on cognitive functioning and slightly
worse on quality of life
4. Local radiation performs slightly better on cognitive functioning and much
worse on quality of life
If outcomes are equally important, most researchers would either (a) set a high
standard and consider local radiation superior if both outcomes demonstrate an
advantage (situation 1), or (b) balance outcomes and consider local radiation
superior if advantages outweigh disadvantages (situations 1–3). Situation 4 is
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unlikely to result in a preference for local radiation, unless cognitive functioning is
much more important than quality of life.
While the All rule applies to the high standard and differentiates situation 1
(superior) from situations 2–4 (not superior), the Compensatory rule balances
results and distinguishes situations 1–3 (superior) from situation 4 (not superior).
The Single and Any rules do not meet these standards and would conclude that
local radiation performs better in all situations, including the fourth. These rules
should be used only when unfavorable effects can safely be ignored in the pres-
ence of a specific (Single rule) or any (Any rule) favorable effect.
Data analysis
To evaluate the decision rules discussed in the previous section, treatment com-
parison requires a procedure to quantify evidence in favor of the new treatment.
The current section introduces the elements of a Bayesian approach to analyze









































































































































































































FIGURE 10.2 Example posterior distributions (left panels) and distributions of the treat-
ment difference (right panels) for four different potential treatment differences (local
radiation–whole-brain radiation) in the CAR-B study
Description of the data and specification of the likelihood
Binary data have two values, traditionally labeled as 1 for success and 0 for fail-
ure. In general, success refers to improvement or absence of decline, and failure
indicates the opposite: decline or absence of improvement respectively. Consid-
ering two outcomes together results in two binary responses per participant that
can take four different combinations (see Table 10.1). The patient can have suc-
cesses on both outcomes (xobs11 ); a success on one outcome, but not on the other
(xobs10 or x
obs
01 ); or failures on both outcomes (x
obs
00 ). The total number of successes
on a particular outcome equals the sum of simultaneous and separate successes
on that outcome, such that xobs1 ¼ xobs11 þ xobs10 , etc.
The multivariate likelihood of the outcomes is based on the four response fre-
quencies. These four response frequencies reflect (a) the individual success rates,
and (b) the relation between outcomes. The latter serves as an additional source
of information that may contribute to more efficient decision-making (Food and
Drug Administration, 2010).
Specification of prior information
Prior information represents prior beliefs about success rates of individual
treatments as well as the difference between treatments. These prior beliefs
can, for example, incorporate information from comparable studies into the
current one. Prior beliefs about two binary outcomes are quantified by four




01 , and x
prior
00 (Olkin & Trikalinos,
2015). Each of these individual prior frequencies incorporates information







veniently, one can think of these prior observations as an extra dataset, where
the total number of observations in this prior dataset reflects the strength of
the prior beliefs. Strong prior beliefs are translated to many prior observations,
whereas weak prior beliefs can be expressed through small numbers of prior
observations. An uninformative prior specification for the analysis of two binary
outcomes would be a half observation for each response combination, such that
the total number of prior observations equals two (Berger, Bernardo, & Sun,
2015). This specification is also called Jeffrey’s prior and conveys virtually no




Success x11 x10 x1
Failure x01 x00 n x1
Total x2 n x2 n
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information about the success rates of individual outcomes or the correlation
between outcomes. If both treatments have this specification, no prior informa-
tion about the treatment difference is provided either.
The posterior distribution
The posterior distribution reflects prior beliefs after they have been updated
with the data and indicate the posterior success rates of individual outcomes in
relation to each other; see also Chapters 1–3 (Miočević, Levy, & Van de
Schoot; Miočević, Levy, & Savord; Van de Schoot, Veen, Smeets, Winter, &
Depaoli). The posterior response frequencies equal the sum of prior and
observed frequencies, such that xpost11 ¼ xprior11 þ xobs11 , etc. Examples of posterior
distributions for treatment effects with two outcomes are graphically presented
in Figure 10.2.
Comparison of the two posterior distributions allows for decision-making
about treatment superiority, by quantifying evidence for a relevant treatment
difference as a posterior probability. This posterior probability depends on the
definition of superiority as defined via the decision rule and allows for two
decisions. If the posterior probability exceeds a pre-specified threshold (often
.95 or .99 in clinical trials; Food and Drug Administration, 2010), evidence is
strong enough to consider the treatment superior. If the posterior probability
is lower than the threshold, there is not sufficient evidence to conclude
superiority.
Computation in practice
The online supplement offers a Shiny app to analyze real data using the frame-
work proposed in the previous sections. If the researcher enters the prior
ðxprior11 ; xprior10 ; xprior01 ; xprior00 Þ and observed ðxobs11 ; xobs10 ; xobs01 ; xobs00 Þ response frequencies for
two treatments, the application:
a. Computes the posterior probability of a treatment difference given the
introduced decision rules
b. Plots the posterior treatment distributions
c. Plots the posterior distribution of the treatment difference
d. Computes the prior, observed and posterior correlations between outcomes
The Shiny app including user guide can be found at https://utrecht-university.
shinyapps.io/multiple_binary_outcomes/ (for the annotated R code and potential
newer versions go to https://github.com/XynthiaKavelaars).
The method and app are illustrated with artificial data from two treatment
distributions with two negatively correlated binary outcome variables (n ¼ 100
cases per treatment). The true success probabilities of the experimental and
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control treatments were .60 and .40 on both outcomes respectively, such that
the experimental treatment performs better on both individual outcomes. The
data were used to quantify evidence in favor of the experimental treatment
according to the different decision rules (Single, Any, All, Compensatory). The
observed response frequencies were entered in the four upper-left cells under
“Experimental treatment” and “Control treatment” in the Data tab (see Figure
10.3). The app subsequently computed the total observed successes and failures
in the margins as well as the observed correlations.
Without any prior knowledge about the treatments or treatment differences,
Jeffrey’s prior served as a prior distribution, such that each response category was
assigned a half observation. After entering the prior frequencies in the Prior tab,
the app provided the successes and failures per outcome and the prior correl-
ation between outcomes (Figure 10.4).
The Treatment distributions tab showed the posterior treatment distributions
and posterior correlations of both treatments (Figure 10.5).
FIGURE 10.3 Screenshot of Data tab
FIGURE 10.4 Screenshot of Prior tab
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The Treatment difference tab (Figure 10.6) presented the distribution of the pos-
terior treatment difference and the evidence in favor of the experimental treat-
ment according to the proposed decision rules.
FIGURE 10.5 Screenshot of Treatment distributions tab
FIGURE 10.6 Screenshot of Treatment difference tab
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Sample size considerations
When the availability of participants is limited, a highly relevant question is how
much data are minimally needed to make a sufficiently powerful decision. Since
the sample size traditionally determines when to stop data collection, researchers
often estimate the required number of participants before running the trial. Effi-
cient a priori sample size estimation is difficult due to uncertainty about one or
multiple treatment differences, regardless of the number of outcomes, since
treatment differences are unknown in advance and need to be estimated. How-
ever, small inaccuracies in their estimation may have important consequences.
Overestimating a treatment difference results in too small a sample to make
a powerful decision, while (limited) underestimation needlessly extends the trial.
In trials with multiple outcomes, the required sample size also depends on the
decision rule as illustrated in Figure 10.7. The figure shows how evidence in
favor of the decision rule under consideration changes for the example data
from the “Computation in practice” section, while increasing the sample size in
steps of one observation per group. Although the posterior probabilities of all
decision rules ultimately approach one and conclude superiority as the data accu-
mulate, different decision rules require different numbers of observations to
arrive at that conclusion. With the data presented in Figure 10.7, the Any rule






















FIGURE 10.7 Example of evidence collection as data accumulate for different decision
rules and two different decision criteria (dots = .95; dashes = .99)
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requires fewest observations to cross decision thresholds, followed by the Com-
pensatory and Single outcome rules. The All rule requires the largest sample.
The relative efficiency of decision rules displayed in Figure 10.7 is specific to the
particular scenario, since different relations between outcomes require different
sample sizes to evaluate a specific decision rule (Food and Drug Administration,
2010). To provide an idea of the influence of the correlation between the out-
comes, posterior treatment distributions for three correlation structures are displayed
in Figure 10.8. This influence affects the proportion of overlap between the distri-
bution of the posterior treatment difference and the superiority region of a decision
rule, such that evidence in favor of the new treatment (i.e. posterior probability) as
well as the required sample size to reach the decision threshold differ.
Figure 10.9 illustrates how the amount of evidence for each decision rule depends
on the correlation when treatment differences are identical. The Single rule is not
sensitive to the correlation: The proportion of the difference distribution that over-
laps with the superiority region is similar for each correlation structure. The
required sample size to conclude superiority will be the same. The All rule has
a (slightly) larger proportion of overlap between the distribution of the difference
and the superiority region when the correlation is positive. Compared to negatively
correlated outcomes, the same amount of evidence can thus be obtained with
a smaller sample. The Any and Compensatory rules demonstrate the relationship
between the correlation structure and sample size more clearly. The distribution of
the treatment difference falls completely in the superiority region when outcomes
are negatively correlated (implying a posterior probability of one), while uncorrel-
ated or positively correlated data result in a part of the distribution outside the
superiority region (i.e. a posterior probability below one). The sample size will be
smallest with negatively correlated outcomes.
In summary, several sources of uncertainty complicate a priori sample size
estimation in trials with multiple outcomes: Treatment differences on individual
outcomes, the correlation between outcomes, and the decision rule influence
the required number of observations. The difficulty of accurately estimating the
sample size interferes with the potential efficiency gain of multiple outcomes,
such that a priori sample size estimation may be inadequate with small samples























































FIGURE 10.8 The influence of the correlation between outcomes on posterior treat-
ment distributions
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Adaptive trial design
To reduce the impact of unknown information on the efficiency of trials the





























































































































































FIGURE 10.9 The influence of the correlation on the evidence for various decision
rules. A larger proportion of overlap between the distribution of the treatment differ-
ence and the superiority region (shaded area) indicates more evidence. CF = cognitive
functioning; QoL = Quality of Life
150 Xynthia Kavelaars
adaptive stopping (Berry, Carlin, Lee, & Muller, 2010). Adaptive stopping per-
forms one or multiple interim analyses and stops the trial as soon as evidence is
conclusive, such that efficiency is optimized. Compared to a priori sample size
estimation, adaptive stopping may result in early trial termination if the treat-
ment difference is larger than expected (i.e. underestimated). If the treatment
difference appears smaller than anticipated (i.e. overestimated) and evidence
remains inconclusive, the trial may be extended beyond the planned sample size.
Adaptive stopping thus forms a flexible alternative that embraces the uncertain-
ties of the traditional a priori estimated sample size (Bauer, Bretz, Dragalin,
König, & Wassmer, 2016; Thorlund, Haggstrom, Park, & Mills, 2018).
Although interim analyses form an attractive approach to improve efficiency,
adaptive trials must be designed carefully (Food and Drug Administration, 2010;
Sanborn & Hills, 2014). The final decision about superiority potentially requires
several interim decisions to evaluate whether evidence is strong enough to draw
a conclusion. Without properly adjusting the design to repeated decision-making,
the risk of falsely concluding superiority (i.e. Type I error) over all decisions is
larger than anticipated, as shown in Figure 10.10 (Sanborn & Hills, 2014). To
keep the Type I error risk over all decisions acceptable, the Type I error rate for
individual decisions must be adjusted (Jennison & Turnbull, 1999). A 5% Type
I error risk over multiple decisions consequentially results in individual decisions
that have a Type I error risk below 5%. The size of the adjustment depends on
the number of interim decisions: More decisions require a larger adjustment of
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FIGURE 10.10 The empirical Type I error probability as a function of the number of
interim analyses for different nmin when the decision threshold is not corrected for the
number of interim analyses. Dashed lines indicate the desired thresholds of α ¼ :05
(posterior probability = .95) and α ¼ :01 (posterior probability = .99)
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A key element in Type I error control is the decision threshold: the lower
limit for the posterior probability to conclude superiority. The decision thresh-
old equals 1α, where α is the maximum Type I error probability (Marsman &
Wagenmakers, 2017). A 5% risk of an incorrect superiority decision (α = .05)
results in a minimal posterior probability of .95. A very high threshold might be
attractive to minimize Type I errors, but does not contribute to efficient deci-
sion-making: A larger sample size is required to regulate the chance to detect
a true treatment difference (i.e. to protect power). The decision threshold thus
relates the Type I error and required sample size via the number of interim ana-
lyses (Shi & Yin, 2019). Limiting the number of decisions is key to efficiently
designing an adaptive trial (Jennison & Turnbull, 1999). To this end, the Food
and Drug Administration (2010) recommends balancing the number of interim
analyses with decision error rates, by carefully choosing three design parameters:
1. The sample size to look at the data for the first time (nmin)
2. The number of added participants if the previous analysis did not provide
sufficient evidence (interim group size)
3. The sample size to stop the trial if evidence is not strong enough to con-
clude superiority (nmax)
The sample size at the first interim analysis (nmin) should not be too small for two
reasons. First, a small interim sample size could detect unrealistically large treatment
effects only and needlessly increases the number of interim analyses. Second, very
small samples increase the probability of falsely concluding superiority (Schönbrodt,
Wagenmakers, Zehetleitner, & Perugini, 2017). As shown in Figure 10.7, the poster-
ior probability is unstable with few observations and becomes more stable as the
number of observations increases. Single observations can be influential in small sam-
ples, and this influence diminishes as the sample size increases. A larger nmin automatic-
ally reduces the number of interim analyses as well as the Type I errors and requires
a smaller correction of the decision threshold, as illustrated in Figure 10.10. However,
a too large nmin limits efficiency: Superiority may have been concluded with a smaller
sample and potential participant recruitment is needlessly extended.
If the first interim analysis did not result in conclusive evidence, the sample size
can be increased in several steps. The interim group size of added participants
should be chosen with the inconclusive results of the previous analysis in mind,
such that the new sample provides a reasonable chance of detecting a treatment dif-
ference given the earlier lack of evidence. The number of observations between
interim analyses may be the same throughout the trial, or can differ per interim ana-
lysis if that would benefit the trial’s efficiency. It should be chosen carefully, how-
ever, since too small and too large group sizes both reduce efficiency (Jennison &
Turnbull, 1999). A too small group size needlessly increases the number of interim
analyses, while a too large group size reduces the flexibility to terminate the trial as
soon as the decision criterion has been met.
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Ideally, the sample size to terminate the trial if the data do not provide suffi-
cient evidence for superiority (nmax) equals the sample size that is required to
detect the smallest treatment effect of clinical interest (Food and Drug Adminis-
tration, 2010). In practice, nmax will often be limited by the maximum number
of available participants and may be smaller than optimal, which has the same
consequence as a too small (a priori estimated) sample size: A limited nmax
restricts the power to detect small treatment differences.
Concluding remarks
The current chapter presented a Bayesian framework for decision-making with
multiple outcomes and illustrated how decisions with two outcomes may help
a small sample, when (a) using a decision rule that combines information from
two outcomes efficiently, and (b) designing a trial adaptively. Without giving all
the mathematical details, I have tried to provide a clear intuition to the approach
and software to carry out the analysis.
The proposed approach has several extensions that may accommodate more
realistic decisions. First, more than two outcomes can be included, such that
researchers might weigh treatment differences on three or more relevant aspects.
Increasing the number of outcomes may further improve efficiency, but more
outcomes also increase the complexity of the data analysis.
Second, although equal importance of outcomes was assumed throughout the chap-
ter, unequal importance of outcomes could be incorporated. The Compensatory rule
in particular could be adapted easily to, for example, include survival into a decision;
an outcome that is in many cases more important than cognitive side effects. How-
ever, user-friendly software packages for more outcomes remain to be developed.
Third, the applicability of adaptive designs can be strongly improved with clear
guidelines on the concrete choice of design parameters. Optimal design of interim
analyses is necessary to do justice to the potential flexibility of adaptive trials.
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